NO20075648L - Vaksinesammensetning - Google Patents

Vaksinesammensetning

Info

Publication number
NO20075648L
NO20075648L NO20075648A NO20075648A NO20075648L NO 20075648 L NO20075648 L NO 20075648L NO 20075648 A NO20075648 A NO 20075648A NO 20075648 A NO20075648 A NO 20075648A NO 20075648 L NO20075648 L NO 20075648L
Authority
NO
Norway
Prior art keywords
vectors
adenoviruses
hiv
relates
methods
Prior art date
Application number
NO20075648A
Other languages
English (en)
Inventor
Peter Franz Ertl
John Philip Tite
Cathrine Ann Van Wely
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075648(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20075648L publication Critical patent/NO20075648L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Foreliggende oppfinnelse angår virusvektorer omfattende oligonukleotider som koder for HIV-polypeptider, mer spesielt hvor virus-vektoren er et adenovirus. Spesielt er slike adenovirus ikke-humane primat-adenovirus så som simian-adenovirus, mer spesielt sjimpanse-adenovirus. Spesielt angår oppfinnelsen adenovirus-vektorer som omfatter HIV- polynukleotidsekvenser som koder for multiple forskjellige HIV-antigener, for eksempel to eller tre eller flere HIV-antigener. Oppfinnelsen angår videre metoder for fremstilling av virus-vektorer, virus-vektorer produsert ved metodene og anvendelse av vektorene i medisin, spesielt profylaktisk eller terapeutisk vaksinasjon.
NO20075648A 2005-05-12 2007-11-06 Vaksinesammensetning NO20075648L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68038905P 2005-05-12 2005-05-12
PCT/EP2006/004854 WO2006120034A1 (en) 2005-05-12 2006-05-10 Vaccine composition

Publications (1)

Publication Number Publication Date
NO20075648L true NO20075648L (no) 2008-02-07

Family

ID=36954770

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075648A NO20075648L (no) 2005-05-12 2007-11-06 Vaksinesammensetning

Country Status (20)

Country Link
US (1) US20090208515A1 (no)
EP (1) EP1880012B1 (no)
JP (2) JP5175178B2 (no)
KR (1) KR101451620B1 (no)
CN (2) CN101384722A (no)
AR (1) AR053275A1 (no)
AU (1) AU2006245920A1 (no)
BR (1) BRPI0608798A2 (no)
CA (1) CA2608316A1 (no)
EA (1) EA200702190A1 (no)
ES (1) ES2546330T3 (no)
IL (1) IL186828A (no)
MA (1) MA29458B1 (no)
MX (1) MX2007014038A (no)
NO (1) NO20075648L (no)
PE (1) PE20061372A1 (no)
SG (1) SG182173A1 (no)
TW (1) TW200716750A (no)
WO (1) WO2006120034A1 (no)
ZA (1) ZA200709518B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL209133B1 (pl) 2001-11-21 2011-07-29 Univ Pennsylvania Rekombinowany adenowirus, obejmująca go izolowana komórka gospodarza, oraz kompozycja i zastosowanie
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
MX362698B (es) * 2007-03-02 2019-02-01 Glaxosmithkline Biologicals Sa Metodo novedoso y composiciones.
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
CN101883857B (zh) * 2007-11-28 2015-08-12 宾夕法尼亚大学托管会 猿猴亚家族B腺病毒SAdV-28、-27、-29、-32、-33和-35及其应用
KR101662574B1 (ko) * 2007-11-28 2016-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
CA2716928C (en) 2008-03-04 2018-04-10 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
RU2609769C2 (ru) 2011-04-06 2017-02-02 Биоваксим Лимитед Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CA2873509A1 (en) 2012-05-18 2013-11-21 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
JP2016513666A (ja) * 2013-03-14 2016-05-16 アムジエン・インコーポレーテツド 組織メタロプロテイナーゼ阻害物質３型（ｔｉｍｐ−３）の変異体、組成物、及び方法
EP3271729B1 (en) 2015-03-18 2020-09-23 Janssen Vaccines & Prevention B.V. Assays for recombinant expression systems
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
AU2016275619B2 (en) * 2015-06-12 2019-09-19 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
US10343884B2 (en) 2015-07-10 2019-07-09 E. & J. Gallo Winery System and method for dispensing a beverage
US11473105B2 (en) 2016-05-12 2022-10-18 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
MX2018015540A (es) 2016-06-20 2019-04-11 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
CN109804075A (zh) 2016-08-01 2019-05-24 威斯塔解剖学和生物学研究所 用于疫苗应用的复制缺陷型腺病毒载体的组合物和方法
WO2018146205A1 (en) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083716A (en) * 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU9456201A (en) * 2000-09-15 2002-03-26 Merck & Co Inc Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
JP2005523233A (ja) * 2001-06-22 2005-08-04 ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー 細胞障害性免疫応答を誘導する方法およびその方法において有用な組み換えサル・アデノウイルス組成物
CA2461056A1 (en) * 2001-09-20 2003-03-27 Glaxo Group Limited Hiv-gag codon-optimised dna vaccines
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
EP1682666B1 (en) * 2003-09-24 2008-12-31 Oxxon Therapeutics Limited HIV Pharmaceutical vaccines
GB2406336A (en) * 2003-09-24 2005-03-30 Oxxon Pharmaccines Ltd HIV Pharmaccines
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
MX2007014038A (es) 2008-02-11
JP5175178B2 (ja) 2013-04-03
CA2608316A1 (en) 2006-11-16
ES2546330T3 (es) 2015-09-22
AU2006245920A1 (en) 2006-11-16
WO2006120034A1 (en) 2006-11-16
SG182173A1 (en) 2012-07-30
ZA200709518B (en) 2014-01-29
CN103088060A (zh) 2013-05-08
TW200716750A (en) 2007-05-01
PE20061372A1 (es) 2007-01-16
IL186828A (en) 2015-06-30
KR101451620B1 (ko) 2014-10-21
US20090208515A1 (en) 2009-08-20
EP1880012A1 (en) 2008-01-23
BRPI0608798A2 (pt) 2011-03-15
CN101384722A (zh) 2009-03-11
EP1880012B1 (en) 2015-07-08
WO2006120034A8 (en) 2007-11-15
JP2008539746A (ja) 2008-11-20
EA200702190A1 (ru) 2008-04-28
KR20080021659A (ko) 2008-03-07
JP2013046613A (ja) 2013-03-07
IL186828A0 (en) 2008-02-09
MA29458B1 (fr) 2008-05-02
AR053275A1 (es) 2007-04-25

Similar Documents

Publication Publication Date Title
NO20075648L (no) Vaksinesammensetning
NO20090194L (no) Rekombinant viral vaksine
Capone et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques
Forrester et al. Recombination in rabbit haemorrhagic disease virus: possible impact on evolution and epidemiology
WO2008014521A3 (en) Improved vaccines and methods for using the same
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
JP2009544333A5 (no)
JP2014534202A5 (no)
RU2019144161A (ru) Последовательности нуклеиновых кислот и аминокислотные последовательности аденовирусов человекообразных обезьян, исключая человека, содержащие их векторы и их применения
RU2015135890A (ru) Композиция вакцины
ATE494906T1 (de) Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
JP2016501015A5 (ja) デングウイルス血清型４（ｄｅｎ−４）構築物に関する組成物、方法および使用
WO2007015783A3 (en) Attenuated strains of flaviviruses , and uses thereof
CY1109036T1 (el) Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
SA518391787B1 (ar) تركيبة لعلاج متلازمة كريغلر نجار
WO2008115314A3 (en) Flavivirus vaccine vector against influenza virus
MXPA05005203A (es) Vacuna contra vhc.
WO2008048984A3 (en) Methods and compositions for preparing a universal influenza vaccine
WO2006073496A3 (en) Recombinant aav based vaccine methods
WO2003076591A3 (en) Compositions and methods for generating an immune response
CO6541529A2 (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
AR067439A1 (es) Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4
UA90098C2 (en) Promoter of vaccinia virus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application